Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGR-1202 and Ibrutinib in B-Cell Malignancies
NCT02268851Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2014
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of umbralisib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) (2 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Dose Limiting Toxicity. Started Nov 2014; status: completed.
02
Drugs
umbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02268851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268851.